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Another win for endothelial progenitor 
cells: Endothelial progenitor cell‑derived 
conditioned medium promotes 
proliferation and exerts neuroprotection 
in cultured neuronal progenitor cells
Nadia Sadanandan, Stefano Di Santo1, Hans Rudolf Widmer1
Abstract:
Progress in stem cell research demonstrates stem cells’ potential for treating neurodegenerative 
diseases. Stem cells have proliferative/differentiative properties and produce a variety of paracrine 
factors that can potentially be used to regenerate nervous tissue. Previous studies have shown the 
positive regenerative effects of endothelial progenitor cells (EPCs), and thus, they may be used 
as a tool for regeneration. A study by Di Santo et al. explored whether EPC‑derived conditioned 
medium (EPC‑CM) promotes the survival of cultured striatal progenitor cells and attempted to find the 
paracrine factors and signaling pathways involved with EPC‑CM’s effects. The neuronal progenitor 
cells that were cultured with EPC‑CM had much higher densities of GABA‑immunoreactive (GABA‑ir) 
neurons. It was shown that phosphatidylinositol‑3‑kinase/AKT and mitogen‑activated protein 
kinase/ERK signaling pathways are involved in the proliferation of GABAergic neurons, as inhibition of 
these pathways decreased GABAergic densities. In addition, the results suggest that paracrine factors 
from EPC, both proteinaceous and lipidic, significantly elevated the viability and/or differentiation in 
the cultures. Importantly, it was found that EPC‑CM provided neuroprotection against toxins from 
3‑nitropropionic acid. In sum, EPC‑CM engendered proliferation and regeneration of the cultured 
striatal cells through paracrine factors and imparted neuroprotection. Furthermore, the effects of 
EPC‑CM may generate a cell‑free therapeutic strategy to address neurodegeneration.
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Novel Discoveries about the 
Potential of Endothelial Progenitor 
Cells as a Therapeutic Tool
Effective treatments for neurodegenerative d iseases  are  s t i l l  l ack ing .  The 
advancements in stem cell research have 
revealed the proliferative and differentiation 
properties of these cells; therefore, these cells 
can hypothetically be used to regenerate 
nervous tissues. Stem cells are not only 
capable of replacing injured cells but also 
have the ability to produce a variety of factors. 
The humoral actions of stem cells, rather 
than transdifferentiation/engraftment, are 
now thought to have the most influence on 
tissue regeneration. Evidence demonstrates 
that bone marrow‑derived endothelial 
precursor cells release paracrine factors 
that increase the viability of various 
tissues. Recent studies have demonstrated 
the potential of endothelial progenitor 
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cell (EPC) “secretome” within its conditioned medium 
form (EPC‑CM).[1‑3] EPCs and their soluble factors have 
also been shown to be successful in treating traumatic 
brain injury, ischemic stroke, and white matter damage 
models. However, the potential of EPCs has often been 
exploited for neurovascular repair.[4‑7]
Effects of Endothelial Progenitor 
Cell‑Derived Conditioned Medium on 
GABA‑immunoreactive Neurons and the 
Cellular Mechanisms Involved
Substantial evidence suggests that stem cells and 
progenitor cells utilize paracrine factors to carry out 
regeneration.[1‑4] Recent studies have demonstrated that 
the viability of brain microvascular cells is significantly 
increased by incubation with EPC‑CM.[3] The recent 
study of Di Santo et al. provided evidence that EPC‑CM 
might support neuronal progenitors from ganglionic 
eminence (GE).[8] To investigate this, primary cultures 
from fetal rat embryonic (E14) GE were utilized, and 
these were grown for 7 days in vitro (DIV). The striatal 
cultures incubated with the EPC‑CM in the DIV5–7 
period were found to have significantly higher densities 
of GABA‑immunoreactive (GABA‑ir) neurons. When 
the mitogen‑activated protein kinase (MAPK) and 
phosphatidylinositol‑3‑kinase (PI3K) pathways were 
inhibited, the effects of EPC‑CM were reduced, as 
the inhibition of the pathways significantly impaired 
EPC‑CM’s ability to increase the density of GABA‑ir 
cells. Similar results occurred when EPC‑CM endured 
proteolytic digestion and lipid extraction, which 
impeded translation. Overall, these results suggest that 
paracrine factors from EPC significantly enhanced the 
survival and/or differentiation in the cultured striatal 
progenitor cells through proteinaceous and lipidic 
factors.
Endothelial Progenitor Cells Produce 
Paracrine Factors that Promote Regeneration
Several studies have documented the regenerative 
potential of EPCs, and their capacity to sustain a 
functional vascular system, which is vital to transporting 
nutrients, signaling molecules, and cells to the site of 
tissue injury.[9‑12] Research from the last decade suggests 
that EPC’s regenerative ability may be effective in more 
than just vascular tissue.[13‑16]
Preclinical trials have shown that EPC paracrine factors 
can be employed as a therapeutic option.[17] Similarly, 
mesenchymal stem cells were found to be a plentiful 
source of paracrine factors and, similar to EPC, can 
potentially be utilized for a wide variety of regenerative 
therapies, such as for myocardial infarction and 
stroke.[18] Furthermore, it has been shown that EPC‑CM 
alleviates ischemic injury in skeletal and myocardial 
muscles.[1,19‑21] In recent studies, EPC‑CM showed 
encouraging neuroprotective capabilities for treating 
ischemic stroke,[22,23] increased the frequency of the 
dopaminergic phenotype in neuronal stem cells,[24] and 
enhanced the number of doublecortin‑positive neuronal 
precursors in the subventricular zone of adult rats.[25]
Endothelial Progenitor Cell‑Derived 
Conditioned Medium Increases GABAergic 
Densities through Cellular Factors and 
Signaling Pathways
The study of Di Santo et al.[8] is the first of its kind to 
specifically examine how EPC‑CM affects progenitor 
striatal cells and aims to identify the cellular components 
and pathways involved. The results of this study 
demonstrated that EPC‑CM increases the densities of 
GABA‑ir neurons through various methods, either 
through greater rates of proliferation and/or increased 
cell viability and differentiation of progenitor neurons. 
The outcome of the Western blot analysis for proliferating 
cell nuclear antigen (a cell proliferation marker) suggests 
that EPC‑CM increased neuronal cell proliferation in 
the cultures. Nevertheless, it is improbable that this 
observation is applicable for the increase in GABAergic 
cell densities observed after day 2 of the treatment. 
The total amount of protein was much higher in the 
cultures treated with EPC‑CM, indicating that EPC‑CM 
enhanced proliferation in other neurons and in other 
cell types. This is also demonstrated by the substantial 
increase of cells expressing the neuronal marker NeuN 
in the EPC‑CM‑treated cultures. In addition, the increase 
of glial fibrillary acidic protein in treated cultures 
demonstrated in the Western blot analysis may also 
imply EPC‑CM’s effects on glial cells.
Equally compelling evidence is  provided on 
characterizing the type of cellular factors (proteinaceous 
and lipidic), and signaling pathways are involved 
with EPC‑CM[8] [Figure 1]. Activation of PI3K/AKT 
and MAPK/ERK signaling cascades promotes the 
neuroprotective effects of EPC‑CM. Through these 
pathways, creatine also stimulated the GABAergic 
phenotype in the striatal cultures.[26]
PI3K/AKT and MAPK/ERK’s role in EPC‑CM‑induced 
effects is not unexpected due to the presence of several 
growth factors: brain‑derived neurotrophic factor, 
glial cell line‑derived neurotrophic factor, neuritin, 
and vascular endothelial growth factor. These growth 
factors are strong inducers of the signaling pathways.[27,28] 
AKT/PI3K signaling plays an important role in the 
central nervous system, as it imparts neuroprotection 
against differing stresses. For example, it provides 
protection against oxidative stress in the adult brain by 
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hindering pro‑apoptotic mechanisms.[29] In the in vitro 
and in vivo models of HD, ERK activation imparts 
neuroprotection.[30] Nonetheless, to depict the role 
of the neurotrophic factors mentioned above in 
EPC‑CM‑induced effects, direct evidence needs to be 
gathered through experiments blocking each of the 
neurotrophic factors. Interestingly, the blockage of the 
ROCK pathway did not reduce EPC‑CM’s impact on 
GABA‑ir cell densities. ROCK is thought to influence 
neurite outgrowth, dendritic branching, and spine 
formation, which are hindered by the expression 
of constitutively activated RhoA.[31‑33] The protein 
translation inhibitor cycloheximide abolished the actions 
of EPC‑CM by blocking translation, suggesting that some 
of EPC‑CM’s effects were carried out indirectly, such as 
through growth factors in autocrine signaling.
The advantages of stem cell secretomes among varying 
clinical conditions have spurred investigations aiming 
to identify the wide range of bioactive molecules 
involved. Although a multitude of peptides present in 
EPC‑CM have been discovered through proteomics,[19,34] 
a thorough examination of the lipidic factors released 
by secretomes has yet to occur. Even though EPC 
releases prostaglandins,[35] it was excluded from this 
study because it cannot be extracted by chloroform.[36] 
Sphingosine‑1‑phosphate (S1P) is an important lipid 
mediator released by bone marrow progenitor cells, 
which include EPC, and mature endothelial cells.[37] 
Importantly, S1P influences neuronal differentiation both 
directly[38] and indirectly through processes involving 
astrocytes.[39] It is thus reasonable to speculate that S1P 
might be involved in the effects of EPC‑CM; however, its 
actual role in EPC‑CM needs to be investigated.
Recent studies reveal that EPC‑CM contains exosomes 
and microvesicles which can transport microRNA.[14,40] 
MicroRNA also acts as a regulator for neurogenesis.[41,42] 
Possibly, the identification of some exosomal cargoes[43] 
might be an easier task compared to the identification of 
the soluble proteins and lipids present in the EPC‑CM.
Endothelial Progenitor Cells Exert 
Neuroprotection
The effects of EPC‑CM are not limited to the enhancement 
of neuronal viability and maturation. Indeed, EPC‑CM 
provided neuroprotection against 3‑NP (an irreversible 
succinate dehydrogenase inhibitor). It can be 
hypothesized that EPC‑CM may be pivotal in treating 
neurodegenerative diseases where energy metabolism 
is lessened on account of an impaired mitochondrial 
complex II and complex III.[44‑46] Mitochondrial 
dysfunction is thought to be a major cause of neuronal 
deterioration in age‑related stroke. Negative conditioning 
of mitochondrial dysfunction can potentially be a 
therapeutic method to ameliorate the quality and 
function of mitochondria.[47] Surprisingly, in the current 
study, EPC‑CM increased the cytoprotective effect of 
viable cells before the tissue injury; however, a change 
in GABA‑ir neuron densities was not observed. This 
suggests that EPC‑CM also bestows cytoprotective effects 
to other cell subpopulations in the neuronal cultures. 
Moreover, 3‑NP also displays toxicity for cultured 
hippocampal, septal, and hypothalamic neurons.[48] In 
addition, EPC‑CM significantly protected dopaminergic 
neurons against 1‑methyl‑4‑phenylpyridinium (MPP+). 
MPP+ toxicity involves the generation of excessive 
oxidative stress and provides an effective tool for 
assessment of neuroprotection on dopaminergic 
neurons.[49] In conclusion, the study suggests that 
EPC‑CM, in conjunction with other methods, may pave 
the way to overcoming neuronal degeneration.
Other Mechanisms that 
Impart Neuroprotection in the Treatment of 
Traumatic Brain Injury and Stroke‑Induced 
Damage
Stroke continues to be the leading cause of death, 
and those who survive the incident endure long‑term 
disabilities. A major type of pharmacological treatment 
is the thrombolytic agent tissue plasminogen activator. 
However, this treatment is not ideal because it 
has a limited therapeutic time window and could 
potentially lead to intracranial hemorrhage. In addition, 
the tissue plasminogen activator fails to provide 
neuroprotection.[50] The development of neuroprotectants 
is of great importance in treating poststroke injuries. 
Recent evidence demonstrates that simple medicinal 
cannabis formulations can function as effective 
neuroprotectants.[51] Hyperbaric oxygen therapy (HBOT) 
is another potential neuroprotective strategy for 
treating ischemic stroke. HBOT preconditioning of 
the brain demonstrates promising results as priming 
Figure 1: Endothelial progenitor cell and neuroprotection. Endothelial progenitor 
cells secrete therapeutic factors, including lipidic and proteinaceous factors. These 
paracrine factors exert neuroprotective effects and exhibit proliferative capacity
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the brain with mild oxidative stress prepares the 
brain for the full‑fledged oxidative stress induced by 
a stroke.[52] Moreover, EPC‑CM may act as an essential 
tool in treating poststroke injuries because EPC‑CM can 
impart neuroprotection as well.
Additional Examples of Trophic Factors and 
Signaling Pathways That May Play a Role 
in Neuronal Regeneration
Stem cell transplantations are becoming a pivotal area 
of research in finding treatments for poststroke injuries. 
Several beneficial effects have been ascribed to stem 
cells in treating ischemic stroke, including secreting 
therapeutic factors around the injured area, initiating 
regeneration, and promoting recovery.[53] An example 
of a trophic factor involved in neural activity after 
stroke is bone morphogenetic protein 7 (BMP7), which 
can promote DNA synthesis. In a rodent distal middle 
cerebral artery occlusion (MCAO) model, treatment 
with BMP7 showed positive results in that sensorimotor 
function improved, body asymmetry decreased, and 
locomotor activity escalated.[54] Thus, proteinaceous 
factors such as BMP7 and those found in EPC‑CM may 
be valuable for treating stroke‑induced injuries.
The study by Di Santo et al.[8] demonstrates that EPC‑CM’s 
effects stem from the activation of signaling pathways 
such as PI3K/AKT and MAPK/ERK. The cascade of 
events, involving both cytotoxic and cytotropic effects, 
that occur in the inflammatory response of the central 
nervous system may be altered to impart regenerative 
properties. In traumatic brain injury or stroke, chronic 
brain inflammation inhibits neuronal regeneration. 
Although the inflammatory response acts as a growth 
inhibitor, it can be altered so that it becomes protective 
and reparative.[55]
The Importance and Efficacy of Conditional 
Medicine for Treating Stroke‑Induced Brain 
Injury and Neurodegenerative Diseases
An array of conditioning stimuli, such as ischemia or 
hypoxia, may provide protection against poststroke brain 
injury.[56] Evidence also suggests that conditional stimuli 
can provide protection to the cerebral vasculature, 
which includes the blood–brain barrier.[56] In addition, 
Parkinson’s disease is associated with a loss in 
dopaminergic neurons. EPC‑CM promoted dopaminergic 
phenotype in neuronal stem cells, and thus, EPC‑CM 
may act as another tool for treating Parkinson’s disease 
and other neurodegenerative disorders. Likewise, a 
study conducted by Leak suggests the efficiency of 
preconditioning dopaminergic neurons in treating 
Parkinson’s disease. In early stages of Parkinson’s 
disease, cells are exposed to mild stress and natural 
defenses escalate. However, as the patient ages, stress 
levels substantially increase to a point where toxic cellular 
responses can no longer be prevented. These results 
suggest that if dopaminergic systems are preconditioned 
with mild stress, the stress would strengthen the cells and 
reduce the toxic effects of stresses that follow.[57] Overall, 
the current neurological research focuses on utilizing 
stem cells such as EPC‑CM, due to their regenerative 
and neuroprotective properties, to treat stroke‑induced 
injuries and other neurodegenerative diseases.
Conclusion
The study by Di Santo et al.[8] investigated whether 
EPCs were capable of spurring proliferation and 
differentiation in striatal progenitor cells. It was found 
that through paracrine factors and signaling pathways, 
EPCs increased GABAergic densities in the cultures. In 
addition, EPCs imparted neuroprotection in the cultures, 
which indicates the potential of EPCs in treating brain 
injury. Therefore, EPCs may become a novel tool for 
conquering neurodegenerative diseases and traumatic 
brain injury.
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